Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

60275 1492790397HCLSReviewGreeceApril2017.pdf
Energy Boardroom

Medicare opens door wide for Gilead's $84K hep C drug Sovaldi

04.06.2014 / Fierce Pharma

The most effective weapon to date against hepatitis C, Gilead's new drug Sovaldi, has raised the ire of drug-cost watchdogs worldwide with its $84,000 price tag. That's not stopping the largest U.S. government payer from giving the product a major push. The Centers for Medicare & Medicaid Services says in a memo that it will start covering hep C screening for adults at high risk for the virus or for any of its beneficiaries who were born between 1945 and 1965.

Cover_HCLS_GREECE LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: